Publications

Click on a program below to view our publications.

Sitravatinib
(MGCD516)KRAS G12C Inhibitor
(MRTX849)

ESMO 2020

Click to view “Sitravatinib in Combination with Nivolumab Demonstrates Clinical Activity in Checkpoint Inhibitor-Naïve, Platinum-Experienced Patients with Advanced or Metastatic Urothelial Carcinoma (a/mUC)”

ASCO 2020

Click to view presentation “Phase 3 Trial of Sitravatinib plus Nivolumab vs Docetaxel for Treatment of NSCLC After Platinum-Based Chemotherapy and Immunotherapy (SAPPHIRE)”

Click to view poster “SNOW: Sitravatinib and Nivolumab in Oral Cavity Cancer Window of Opportunity Study”

ASCO GU 2020

Click to view “ASCO GU 2020 – A Phase 1-2 Trial of Sitravatinib Combined with Nivolumab in Patients with Advanced Clear Cell Renal Cell Cancer that Progressed on Prior Anti-Angiogenic Therapy”

SITC 2019

Click to view poster “SNOW: Sitravatinib and Nivolumab in Oral Cavity Cancer Window of Opportunity Study”

Click to view presentation “Sitravatinib + Nivolumab Demonstrates Clinical Activity in Platinum-Experienced Urothelial Carcinoma Patients Who Progressed on Prior Checkpoint Inhibitor”

IASLC WCLC 2019

Click to view “Phase 3 Trial of Sitravatinib plus Nivolumab vs Docetaxel for Treatment of NSCLC after Platinum-Based Chemoimmunotherapy”

ASCO Genitourinary Cancers Symposium 2019

Click to view “Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (UC) after Checkpoint Inhibitor Therapy (CIT)”

Click to view “Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma (ccRCC)”

SITC 2018

Click to view “Preliminary Biomarker Analysis of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor”

ESMO 2018

Click to view “Stage 2 Enrollment Complete: Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy”

Click to view “Sitravatinib Demonst/wp-content/uploads/2020/02/20180921_ESMO-2018-MRTX-500-Stage-2-Enrollment-Complete-Sitravatinib-in-Combination-witrates Activity in Patients with Novel Genetic Alterations that Inactivate CBL”

ASCO 2018

Click to view “Evaluation of the spectrum selective RTK inhibitor in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy”

World Conference on Lung Cancer 2017

Click to view “Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy”

Click to view “CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib”

IASLC 2017 CHICAGO

Click to view “CBL Mutations as Potential Mediators of EGFR TKI Resistance Effectively Treated with Sitravatinib”

IASLC 2016 TiP Poster #4109

Click to view “A study of MGCD516, a receptor tyrosine kinase (RTK) inhibitor, in molecularly selected patients with NSCLC or other advanced solid tumors”

IASLC 2016 TiP Poster #4795

Click to view “Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy”

ASCO 2016 Poster #2575

Click to view “A First-in-Human Phase 1 Study of Receptor Tyrosine Kinase (RTK) Inhibitor MGCD516 in Patients with Advanced Solid Tumors“

AACR Part II 2020

Click to view “The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models”

Click to view “Drug-Anchored in vitro and in vivo CRISPR Screens to Identify Targetable Vulnerabilities and Modifiers of Response to MRTX849 in KRAS G12C-Mutant Models”

Research Article, Journal of Medicinal Chemistry, April 2020

Click to view “Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12CInhibitor for the Treatment of Cancer”

Research Article, Journal of Internal Medicine, March 2020

Click to view “Targeting KRASG12C‐Mutant Cancer with a Mutation‐Specific Inhibitor”

2019 AACR-NCI-EORTC Conference

Click to view poster “The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment”

Click to view poster “Discovery and Preclinical Development of MRTX849 A Mutation-Selective KRAS G12C Inhibitor”

Click to view “Pre-Clinical Data Presentation – Christensen – October 2019”

Click to view “Clinical Data Presentation – Janne – October 2019″

Research Article, Cancer Discovery, Oct. 2019

Click to View Christensen, J.G. et al, The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients, Cancer Discov October 28 2019 DOI: 10.1158/2159-8290.CD-19-1167

2019 ASCO CONFERENCE

Click to view “A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation”

2019 AACR CONFERENCE

Click to view “Insight Towards Therapeutic Susceptibility of KRAS Mutant Cancers from MRTX1257, a Novel KRAS G12C Mutant-Selective Small Molecule Inhibitor”

2018 AACR-RAS Conference

Click to view “Structure-Based Drug Discovery of MRTX1257, a Selective, Covalent KRAS G12C Inhibitor with Oral Activity in Animal Models of Cancer”

Click to view “Insight Towards Therapeutic Susceptibility of KRAS Mutant Cancers from MRTX1257: A Prototype Selective Inhibitor of KRAS G12C”

ACS 2018

Click to view “Structure-Based Drug Discovery of a Selective, Covalent KRAS G12C Inhibitor with Oral Activity in Animal Models of Cancer”